Quarterly ResultMay 7, 2026, 08:18 AM
Silence Therapeutics Q1 Net Loss $15.0M; Divesiran Phase 2 Results on Track
AI Summary
Silence Therapeutics plc reported its financial results for the first quarter ended March 31, 2026, with a net loss of $15.0 million, a significant improvement from $28.5 million in the prior year, primarily due to lower R&D expenses. The company also provided an update on recent business achievements, including the SANRECO Phase 2 trial of divesiran for polycythemia vera remaining on track for topline results in August 2026. Additionally, an abstract for the SLN312 Phase 1 study for dyslipidemia was accepted for a late-breaking oral presentation.
Key Highlights
- SANRECO Phase 2 trial of divesiran for PV on track for topline results in August 2026.
- Cash, cash equivalents, and short-term investments were $70.1 million as of March 31, 2026.
- Net loss for Q1 2026 was $15.0 million, compared to $28.5 million in Q1 2025.
- R&D expenses decreased to $9.1 million in Q1 2026 from $20.8 million in Q1 2025.
- Collaboration revenue was $0.4 million in Q1 2026, up from $0.1 million in Q1 2025.
- G&A expenses were $7.0 million in Q1 2026, down from $7.7 million in Q1 2025.
- Loss per share was $0.11 (basic and diluted) for Q1 2026, compared to $0.20 in Q1 2025.